Stein Jason,Weiser Michael,Capriotti Joseph,Liang Bo,Samson C. Michael
申请号：
NZ71757312
公开号：
NZ717573A
申请日:
2012.05.11
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Disclosed are stable ophthalmic composition, comprising: 0.3 to 1% (w/w) polyvinylpyrrolidinone-iodine complex 0.05 to 2% (w/w) non-steroidal anti-inflammatory drug (NSAID) bromfenac, or 0.05 to 2% (w/w) steroid selected from the group consisting of prednisolone acetate, loteprednol etabonate, difluprednate, hydrocortisone acetate, and combinations thereof 0.005% to 0.02% (w/w) EDTA 0.01 to 0.5% (w/w) sodium chloride 0.02 to 0.1% (w/w) tyloxapol as a co-solvent/surfactant 0.5% to 2% (w/w) sodium sulfate and 0.1 to 0.5% (w/w) hydroxyethylcellulose as a viscosity increasing agent. These ophthalmic compositions are suitable for the treatment and/or prophylaxis of an eye disorder selected from the group consisting of a microorganism infection of at least one tissue of the eye, conjunctivitis, corneal abrasion, ulcerative infectious keratitis, epithelial keratitis, stromal keratitis and herpesvirus-related keratitis.
